Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PIPAC with Novel NDDS for Peritoneal Metastatic Adenocarcinoma
NCT06743867Phase 1Recruiting
- Sponsor
- Guangdong Provincial People's Hospital
- Start
- Dec 2024
- Primary completion
- Sep 2026
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of cisplatin, doxorubicin and oxaliplatin in Adenocarcinoma, sponsored by Guangdong Provincial People's Hospital. Primary endpoints: Adverse Events (AE) and serious AE associated with Treatment, Incidences of device defects and 2 more. Started Dec 2024; status: recruiting.
02
Drugs
cisplatindoxorubicinoxaliplatin
03
Conditions
Adenocarcinoma
Beyond the preview
Go deeper on NCT06743867.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06743867.